Literature DB >> 3881537

Molecular characteristics of SS-B/La and SS-A/Ro cellular antigens.

J S Deng, R D Sontheimer, J N Gilliam.   

Abstract

Anti-SS-B/La and anti-SS-A/Ro antibodies coexist in certain patients with connective tissue diseases such as systemic lupus erythematosus or Sjögren's syndrome. The respective antigenic structures with which these autoantibodies bind have not been fully characterized. The present study was conducted to better define these two different cellular antigens. WiL2 cell extracts were used to obtain partially purified SS-B/La and SS-A/Ro antigens. Both were found to be present in most fractions obtained after sequential purification with ammonium sulfate salt precipitation, G-200 gel filtration, DE-52 ion exchange chromatography, and preparative slab gel electrophoresis. However, SS-B/La antigenic activity was also found to be present in some fractions that did not contain detectable SS-A/Ro activity. These findings suggested the existence of two different forms of SS-B/La antigen: one containing the SS-B/La antigen only and the other containing both the SS-B/La and SS-A/Ro antigens. The RNA and protein components of these two ribonuclear protein particles were further defined by immunoprecipitation experiments using 32P-labeled WiL2 cell extract. The SS-B/La antigen was found to be associated with several RNAs while the SS-A/Ro antigen was associated with several other distinct RNAs. Both antibodies precipitated a common 43K molecular weight phosphoprotein. The antigenic peptides of these 2 antibodies were analyzed using an immunoblot system. The SS-B/La antigen was present on a 43K peptide which was unstable and could be degraded to several peptides of lower molecular weight (40K, 38K, 30K), while the SS-A/Ro antigen occurred on a peptide having a molecular weight of about 60K.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3881537     DOI: 10.1111/1523-1747.ep12274950

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

Review 1.  Congenital AV-block: role of anti-Ro and anti-La antibodies.

Authors:  J S Scott; P V Taylor
Journal:  Springer Semin Immunopathol       Date:  1989

Review 2.  Passively acquired autoimmunity and the maternal fetal dyad in systemic lupus erythematosus.

Authors:  J Buyon; I Szer
Journal:  Springer Semin Immunopathol       Date:  1986

3.  PUVA treatment of human cultured fibroblasts from psoriatic skin enhances the binding of antibodies to SSA(Ro).

Authors:  U Wollina; H Beensen; L Kittler; H Schaarschmidt; B Knopf
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

4.  Biochemical and immunological heterogeneity of the Ro ribonucleoprotein particles. Analysis with sera specific for the RohY5 particle.

Authors:  G Boire; J Craft
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

Review 5.  Immunopathologic studies of cutaneous lupus erythematosus.

Authors:  T T Provost; M Reichlin
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

6.  Human Ro ribonucleoprotein particles: characterization of native structure and stable association with the La polypeptide.

Authors:  G Boire; J Craft
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

7.  Higher incidences of anti-SS-A/Ro and anti-SS-B/La autoantibodies in Japanese patients with autoimmune disorders--studies of antigens and antibodies using the immunoblotting method.

Authors:  Y Inagaki; Y Jinno; Y Hamasaki; H Ueki
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

8.  Acquired congenital heart block. Pattern of maternal antibody response to biochemically defined antigens of the SSA/Ro-SSB/La system in neonatal lupus.

Authors:  J P Buyon; E Ben-Chetrit; S Karp; R A Roubey; L Pompeo; W H Reeves; E M Tan; R Winchester
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

9.  A 52-kD protein is a novel component of the SS-A/Ro antigenic particle.

Authors:  E Ben-Chetrit; E K Chan; K F Sullivan; E M Tan
Journal:  J Exp Med       Date:  1988-05-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.